Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rhythm Biosciences Ltd. reports advancements in ColoSTAT®, a blood test for colorectal cancer detection, with enhancements to assay quality and clinical strategy. The company has completed a successful fundraising Rights Issue, raising approximately $2.75 million, and is focusing on an expanded cancer diagnostic portfolio. Additionally, a new CEO, Dr. David Atkins, has taken executive leadership, and a Board composition review is underway to align with strategic goals.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.